Equity Overview
Price & Market Data
Price: $1.66
Daily Change: -$0.03 / 1.81%
Daily Range: $0 - $0
Market Cap: $103,128,984
Daily Volume: 0
Performance Metrics
1 Week: 15.07%
1 Month: 23.53%
3 Months: 17.48%
6 Months: -86.61%
1 Year: -87.00%
YTD: -87.24%
Company Details
Employees: 171
Sector: Health technology
Industry: Biotechnology
Country:
Details
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.